Jan Kuhlmann

638 total citations
21 papers, 444 citations indexed

About

Jan Kuhlmann is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jan Kuhlmann has authored 21 papers receiving a total of 444 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Surgery and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jan Kuhlmann's work include Colorectal Cancer Treatments and Studies (6 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Jan Kuhlmann is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (6 papers) and Hepatocellular Carcinoma Treatment and Prognosis (4 papers). Jan Kuhlmann collaborates with scholars based in Germany, Austria and United States. Jan Kuhlmann's co-authors include Hubert E. Blum, Richard Fischer, Dirk Strumberg, Jan Harder, Hans Christian Spangenberg, Beate Schultheis, Wulf Euringer, Matthias Breidert, K. Mross and Uwe Pelzer and has published in prestigious journals such as Journal of Clinical Oncology, BMJ and Annals of Oncology.

In The Last Decade

Jan Kuhlmann

20 papers receiving 435 citations

Peers

Jan Kuhlmann
Amélie Deleporte Belgium
Keum Ha Choi South Korea
Hajime Yokomizo Japan
Eiki Ojima Japan
Cathy Fan United States
Erienne M.V. de Cuba Netherlands
Zhangheng Huang China
Sergio Valeri Italy
Thilo Sprenger Germany
Amélie Deleporte Belgium
Jan Kuhlmann
Citations per year, relative to Jan Kuhlmann Jan Kuhlmann (= 1×) peers Amélie Deleporte

Countries citing papers authored by Jan Kuhlmann

Since Specialization
Citations

This map shows the geographic impact of Jan Kuhlmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Kuhlmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Kuhlmann more than expected).

Fields of papers citing papers by Jan Kuhlmann

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Kuhlmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Kuhlmann. The network helps show where Jan Kuhlmann may publish in the future.

Co-authorship network of co-authors of Jan Kuhlmann

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Kuhlmann. A scholar is included among the top collaborators of Jan Kuhlmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Kuhlmann. Jan Kuhlmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Kern, Johannes S., Kristin Technau‐Hafsi, H Schwacha, et al.. (2016). Esophageal involvement is frequent in lichen planus: study in 32 patients with suggestion of clinicopathologic diagnostic criteria and therapeutic implications. European Journal of Gastroenterology & Hepatology. 28(12). 1374–1382. 32 indexed citations
3.
Schultheis, Beate, Dirk Strumberg, Jan Kuhlmann, et al.. (2016). A phase Ib/IIa study of combination therapy with gemcitabine and Atu027 in patients with locally advanced or metastatic pancreatic adenocarcinoma.. Journal of Clinical Oncology. 34(4_suppl). 385–385. 38 indexed citations
4.
Schmoll, Hans‐Joachim, Jorge Riera‐Knorrenschild, Hans‐Georg Kopp, et al.. (2015). Maintenance therapy with the TLR-9 agonist MGN1703 in the phase II IMPACT study of metastatic colorectal cancer patients: A subgroup with improved overall survival.. Journal of Clinical Oncology. 33(3_suppl). 680–680. 6 indexed citations
5.
Rau, Beate, Markus Loeffler, U. Sulkowski, et al.. (2015). Perioperative chemotherapy and cytoreductive surgery with versus without HIPEC in gastric cancer with limited peritoneal metastases: A randomized phase III study (GASTRIPEC).. Journal of Clinical Oncology. 33(15_suppl). TPS4132–TPS4132. 11 indexed citations
6.
Vogel, Arndt, Stefan Kasper, Wilko Weichert, et al.. (2015). Panitumumab in combination with gemcitabine/cisplatin (GemCis) for patients with advanced kRAS WT biliary tract cancer: A randomized phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO).. Journal of Clinical Oncology. 33(15_suppl). 4082–4082. 11 indexed citations
7.
Riera‐Knorrenschild, Jorge, Dirk Arnold, Hans‐Georg Kopp, et al.. (2015). A subgroup with improved overall survival from the phase 2 IMPACT study: Maintenance therapy of metastatic colorectal cancer patients with the TLR-9 agonist MGN1703.. Journal of Clinical Oncology. 33(15_suppl). 3049–3049. 2 indexed citations
8.
Mross, K., M. E. Scheulen, Dirk Strumberg, et al.. (2014). FOLFIRI and sunitinib as first-line treatment in metastatic colorectal cancer patients with liver metastases â a CESAR phase II study including pharmacokinetic, biomarker, and imaging data. International Journal of Clinical Pharmacology and Therapeutics. 52(8). 642–652. 6 indexed citations
9.
Scheithauer, Werner, Jorge Riera‐Knorrenschild, Hans‐Georg Kopp, et al.. (2014). Long-Term Maintenance Therapy with the TLR-9 Agonist MGN1703 in a Subgroup of Metastatic Colorectal Cancer Patients from the Impact Study. Annals of Oncology. 25. vi1–vi1. 1 indexed citations
10.
Kuhlmann, Jan & Hubert E. Blum. (2013). Locoregional therapy for cholangiocarcinoma. Current Opinion in Gastroenterology. 29(3). 324–328. 36 indexed citations
11.
Schultheis, Beate, Gunnar Folprecht, Jan Kuhlmann, et al.. (2013). Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Annals of Oncology. 24(6). 1560–1567. 78 indexed citations
12.
Brass, Volker, Jan Kuhlmann, & Hubert E. Blum. (2013). Current state of nonsurgical therapies for cholangiocarcinoma. PubMed. 1(1). 135–142.
13.
Kuhlmann, Jan, Wulf Euringer, Hans Christian Spangenberg, et al.. (2012). Treatment of unresectable cholangiocarcinoma. European Journal of Gastroenterology & Hepatology. 24(4). 1–1. 96 indexed citations
14.
Kuhlmann, Jan. (2012). Treatment of Advanced Cholangiocarcinoma: Current Status and Future Perspectives. 63–67. 1 indexed citations
15.
Kuhlmann, Jan, Hubert E. Blum, Wolfgang Kreisel, & R. Fischer. (2011). A severe case of odynophagia. BMJ. 343(jul13 2). d3137–d3137. 1 indexed citations
16.
Schultheis, Beate, Gunnar Folprecht, Jan Kuhlmann, et al.. (2011). Phase I study of regorafenib sequentially administered with either FOLFOX or FOLFIRI in patients with first-/second-line colorectal cancer.. Journal of Clinical Oncology. 29(15_suppl). 3585–3585. 11 indexed citations
17.
Schultheis, Beate, Gunnar Folprecht, Jan Kuhlmann, et al.. (2011). FOLFOX or FOLFIRI in combination with sequentially administered regorafenib as first- or second-line treatment in patients with colorectal cancer. 1 indexed citations
18.
19.
Mross, K., Annette Frost, Jan Kuhlmann, et al.. (2008). A randomized open-label phase I study to assess the effect of vandetanib on vascular permeability in patients with advanced colorectal cancer and liver metastases. Journal of Clinical Oncology. 26(15_suppl). 4113–4113. 1 indexed citations
20.
Zühlsdorf, M, et al.. (2004). Glucuronidation of acetaminophen is independent of UGT1A1 promotor genotype. International Journal of Clinical Pharmacology and Therapeutics. 42(2). 73–77. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Amélie Deleporte Breakdown of academic impact, for papers by Keum Ha Choi Breakdown of academic impact, for papers by Hajime Yokomizo Breakdown of academic impact, for papers by Eiki Ojima Breakdown of academic impact, for papers by Cathy Fan Breakdown of academic impact, for papers by Erienne M.V. de Cuba Breakdown of academic impact, for papers by Zhangheng Huang Breakdown of academic impact, for papers by Sergio Valeri Breakdown of academic impact, for papers by Thilo Sprenger
Rankless by CCL
2026